HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leung, W.T. Articles by Li, A.K.C. Search for Related Content PubMed PubMed Citation Articles by Leung, W.T. Articles by Li, A.K.C.

Selective Internal Radiation Therapy with Intra-arterial Iodine-131-Lipiodol in Inoperable Hepatocellular Carcinoma

The Joint Hepatoma Clinic, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

Correspondence: For correspondence or reprints contact: Dr. W.T. Leung, Dept. of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

ABSTRACT

From August 1990 to June 1993, 26 patients with inoperable hepatocellular carcinoma were treated with intra-arterial iodine-131-Lipiodol (¹³¹I-L). Methods: Iodine-131-Lipiodol was given through either an implantable arterial port (9 patients) or during hepatic angiography (17 patients). All 26 patients had multiple lesions, 3 had involved resection margin after surgical resection and 1 had diffuse infiltrative lesions. The median size of the largest tumor among 22 patients with a measurable lesion was 4.5 cm (2–9.5 cm). The end points are tumor response in terms of tumor size, change in serum alpha-fetoprotein level, toxicity of treatment and overall survival. Results: Twenty-three patients received a single treatment of 1.11–2.22 GBq (30–60 mCi)¹³¹I-L. Three patients received 2.22–4.44 GBq (60–120 mCi)¹³¹I-L in three fractions. Considering both radiological regression and reduction in serum alpha-fetoprotein level as objective response criteria, the overall response rate was 52% (13 out of 25 patients with evaluable disease). Ten out of 15 patients who had raised alpha-fetoprotein levels had more than 50% reduction and 8 patients had more than 90% reduction in alpha-fetoprotein level. Since analysis, 19 patients have died and 7 remain alive, giving a minimum median survival of 6 mo (range 1.2–16.6 mo), with 4 surviving more than 1 yr calculated from the day of treatment. There was only one patient who had late deterioration of liver function compatible with radiation hepatitis. There was no bone marrow toxicity documented in any patients. Conclusion: Treatment with intra-arterial ¹³¹I-L was well tolerated in patients with inoperable hepatocellular carcinoma and produced an objective response of 52% with median survival of 6 mo. A fractionated dose of ¹³¹I-L was feasible and the radiation dose could be escalated safely.

Key Words: hepatocellular carcinoma • iodine-131-lipiodol • selective internal radiation

This article has been cited by other articles:

				C. O. Wong, N. Pandit-Taskar, and S. M. Larson JNM Supplement on Molecular Radiotherapy J. Nucl. Med., October 1, 2005; 46(10): 1765 - 1766. [Full Text] [PDF]

				B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Van Vlierberghe, J. M. Jeong, R. A. Dierckx, C. Van de Wiele, H. Thierens, and F. De Vos 188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial J. Nucl. Med., January 1, 2005; 46(1): 60 - 66. [Abstract] [Full Text] [PDF]

				S. Badvie Hepatocellular carcinoma Postgrad. Med. J., January 1, 2000; 76(891): 4 - 11. [Abstract] [Full Text]

				T. de Baere, P. Taourel, J. M. Tubiana, V. Kuoch, M. Ducreux, J. Lumbroso, and A. J. Roche Hepatic Intraarterial 131I Iodized Oil for Treatment of Hepatocellular Carcinoma in Patients with Impeded Portal Venous Flow Radiology, September 1, 1999; 212(3): 665 - 668. [Abstract] [Full Text]